4.3 Article

Use of big data for drug development and for public and personal health and care

Journal

GENETIC EPIDEMIOLOGY
Volume 41, Issue 1, Pages 51-60

Publisher

WILEY-BLACKWELL
DOI: 10.1002/gepi.22012

Keywords

bioinformatics; healthcare; health systems; personalized medicine; data commons; public health; public health genomics; structured data; unstructured data; drug development; safety monitoring; health policy; comparative effectiveness research; knowledge visualization; cognitive computing

Ask authors/readers for more resources

The use of data analytics across the entire healthcare value chain, from drug discovery and development through epidemiology to informed clinical decision for patients or policy making for public health, has seen an explosion in the recent years. The increase in quantity and variety of data available together with the improvement of storing capabilities and analytical tools offer numerous possibilities to all stakeholders (manufacturers, regulators, payers, healthcare providers, decision makers, researchers) but most importantly, it has the potential to improve general health outcomes if we learn how to exploit it in the right way. This article looks at the different sources of data and the importance of unstructured data. It goes on to summarize current and potential future uses in drug discovery, development, and monitoring as well as in public and personal healthcare; including examples of good practice and recent developments. Finally, we discuss the main practical and ethical challenges to unravel the full potential of big data in healthcare and conclude that all stakeholders need to work together towards the common goal of making sense of the available data for the common good.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available